The results come several months after the FDA approved Lisraya for dermatomyositis.
|Articles|September 1, 2003
September FDA Pipeline
Recent approvals and new indications
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
As psychedelic drugs near FDA decisions, people with HIV remain absent from trials, commentary says
2
Payment integrity is necessary. But timing determines its impact
3
A new strategy for secondary stroke prevention gets boost from FDA approval
4
Positive phase 2 results reported for Lisraya as a treatment for cutaneous sarcoidosis
5